华东医药：子公司依达拉奉片上市许可申请获受理

Core Viewpoint - Huadong Medicine's subsidiary, Sino-American Huadong, has received a notice of acceptance from the National Medical Products Administration for its application to market edaravone tablets for the treatment of acute ischemic stroke [1] Group 1: Company Developments - The application for edaravone tablets (R&D code: TTYP01) has been officially accepted, indicating progress in the drug approval process [1] - Edaravone is considered a significant drug in the neurology field, highlighting the company's focus on innovative treatments [1] Group 2: Industry Implications - The oral formulation of edaravone tablets is expected to reduce the consumption of medical resources compared to the intravenous administration of edaravone, which is typically given in hospitals for 14 days [1] - The ability for patients to self-administer the oral tablets may enhance treatment adherence and improve patient outcomes in the long term [1]